GNCA NASDAQ
Cambridge, MA 02140
US
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Duvall Diantha | S-Sale | 1,355 | $0.06 | 2022-06-02 |
| Flechtner Jessica Ba | S-Sale | 1,578 | $0.06 | 2022-06-02 |
| Clark William D | S-Sale | 4,023 | $0.06 | 2022-06-02 |
| SUMER JACQUELYN L | S-Sale | 2,500 | $0.06 | 2022-06-01 |
| Clark William D | S-Sale | 117,244 | $0.06 | 2022-05-31 |